Our study clearly reveals that prolonged expression of IL-10, IL-12p40,
TNF-α, MCP-1, and MIP-2 in corneal grafts is not correlated with
rejection. This is consistent with our previous study, in which we
showed IL-10, MCP-1, and MIP-2 mRNA expression in nonrejected
autografts.
12 It has been hypothesized that IL-10 may
contribute to graft survival by blocking cytokine production and
downregulating MHC class II expression.
34 Several studies
showed that topical treatment with IL-10 reduced corneal inflammation
after herpes simplex virus infection.
35 36 However, local
treatment with IL-10 during corneal transplantation did not prolong
allograft survival.
37 Although TNF-α, MCP-1, and MIP-2
are considered to be inflammatory mediators,
19 and IL-12 a
pivotal factor in the development of Th1 responses,
38 their role in graft rejection remains largely unknown. A number of
studies have indicated that IL-12 and TNF-α may have a beneficial
role in graft acceptance. Interleukin-12 expression was found in
long-term cardiac allografts after rapamycin treatment.
39 Moreover, IL-12 antagonism, by antibodies or an IL-12p40 homodimer
receptor antagonist, exacerbated cardiac allograft
rejection.
40 Interestingly, Voest et al.
41 have reported that IL-12 is capable of blocking corneal
neovascularization. In view of this activity, expression of IL-12 in
the cornea after transplantation may serve to limit angiogenesis. With
regard to TNF, it has been shown that systemic administration of this
cytokine decreased skin allograft rejection.
42 This
tolerogenic effect may result from a strong inhibition of the
antigen presenting capacity of dendritic cells by TNF.
43